Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fosun Pitches for India's Gland

Executive Summary

Shanghai Fosun Pharmaceutical Group Co. Ltd. has confirmed it interest in the Indian injectables firm, Gland Pharma Ltd., underscoring how differentiated niche plays continue to attract buyer interest.

You may also be interested in...



Torrent On Course For Buy, US Momentum

Torrent Pharmaceuticals Ltd may have opted out of the race for the injectables firm Gland Pharma Ltd, but the Indian company stays interested in a buy to build its "hospital presence".

PharmAsia News Business Bulletin

A new regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.

KKR invests $200m in India's Gland

Niche verticals such as injectables continue to attract private equity (PE) interest in India, with the global investment firm, KKR, acquiring a minority stake in Gland Pharma for about $200m – the largest PE investment in a local pharmaceutical firm in recent times.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel